NiCCC
SGCTG - NSGO

Trial setting: tumour type/stage	Progressive or recurrent ovarian and endometrial CCC within 6 months of previous platinum
Study Design:	Open Label Randomised Phase II Study
Sponsor:	NHS Greater Glasgow & Clyde
Planned No. of patients:	90 Ovarian and up to 30 endometrial
Current accrual:	32
Other important information:	Open Sites: UK: 16, France: 16
Additional Participating Countries:	The Netherlands, Denmark, Spain, Portugal, Italy, Belgium still to open

NiCCC

Trial Design

90 pts with progressive or relapsed CCC of ovary within 6 months of previous platinum.

Plus up to 30 women with endometrial CCC

RANDOMISE

Control Arm: Chemotherapy

Ovary:

- PLD (40mg/m^2 day 1q28)
- Weekly Paclitaxel (80mg/m^2 day 1, 8, 15 q28)
- Weekly Topotecan IV (4mg/m^2 day 1, 8, 15 q28)

Endometrium:

- Carboplatin (AUC 5) /Paclitaxel 175 mg/m^2 q21
- Doxorubicin 60mg/m^2 q21

Experimental Arm: Nintedanib

Nintedanib 200mg bd until progression



Primary Endpoint: PFS

Secondary Endpoints: OS, Toxicity, RR, QoL, Q-Twist